Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
J Biol Chem 278(38):3593135939
The product is not intended to diagnose, treat, cure or prevent any disease. Hormone imbalance is a growing issue for many people today
:format(webp))
Quintana-Cabrera et al., 2012)
There is a growing demand for effective treatments that go beyond traditional insulin therapy, as sedentary lifestyles, unhealthy diets, and aging populations contribute to the increasing incidence of metabolic disorders worldwide
When a patient needs stronger metabolic effects, the standard approach is to increase the weekly dose at appropriate intervals, not to inject more often
The SELECT trial (2023) further demonstrated semaglutide 2.4 mg significantly reduced MACE risk in non-diabetic adults with obesity and established CV disease, supporting Wegovy's CV indication
US$ 20.86
US$ 22.67
US$ 21.81
US$ 28.71
US$ 24.28
